Amicus Therapeutics Inc. (NASDAQ:FOLD) CFO William D. Baird III sold 20,500 shares of Amicus Therapeutics stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $8.00, for a total value of $164,000.00. Following the transaction, the chief financial officer now owns 56,450 shares of the company’s stock, valued at approximately $451,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) opened at 7.79 on Friday. The firm’s market capitalization is $1.11 billion. The firm’s 50-day moving average is $7.02 and its 200 day moving average is $6.96. Amicus Therapeutics Inc. has a 12 month low of $4.98 and a 12 month high of $15.56.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.07. On average, equities research analysts anticipate that Amicus Therapeutics Inc. will post ($1.35) EPS for the current year.

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in Amicus Therapeutics by 19.8% in the second quarter. Bank of New York Mellon Corp now owns 649,235 shares of the biopharmaceutical company’s stock worth $3,545,000 after buying an additional 107,215 shares in the last quarter. GW&K Investment Management LLC raised its stake in Amicus Therapeutics by 12.3% in the second quarter. GW&K Investment Management LLC now owns 468,708 shares of the biopharmaceutical company’s stock worth $2,559,000 after buying an additional 51,273 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in Amicus Therapeutics by 14.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 709,900 shares of the biopharmaceutical company’s stock worth $3,876,000 after buying an additional 90,000 shares in the last quarter. Squarepoint Ops LLC raised its stake in Amicus Therapeutics by 101.9% in the first quarter. Squarepoint Ops LLC now owns 83,600 shares of the biopharmaceutical company’s stock worth $706,000 after buying an additional 42,200 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in Amicus Therapeutics by 14.4% in the first quarter. Legal & General Group Plc now owns 29,770 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 3,743 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

A number of equities analysts recently commented on FOLD shares. Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a report on Monday, July 25th. Leerink Swann reiterated an “outperform” rating and set a $19.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a report on Tuesday, June 14th. Finally, Chardan Capital set a $15.00 price target on Amicus Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $12.19.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.